VANCOUVER, April 17, 2018 /CNW/ - Cognetivity Neurosciences Ltd. (the "Company" or "Cognetivity") (CSE: CGN) today announced that it has been selected to present landmark results from its ongoing research into the early detection of cognitive impairment to a distinguished group of academic and biopharma industry experts at the notable European Laboratory Research and Innovation Group (ELRIG), Research and Innovation Meeting, held in Cambridge, UK.
ELRIG, a not-for-profit organization based in the UK, is recognized as a leader in the provision of scientific meetings and conferences which bring together academic and biopharma industry experts and thought leaders to exchange ideas and information.
In a talk titled 'Artificial Intelligence-Based Assessment of Cognitive Impairment in Neurodegenerative Diseases', Cognetivity's Chief Scientific Officer, Dr. Seyed-Mahdi Khaligh-Razavi will present an overview of the company's unique AI-based approach, and deliver positive results from ongoing trials into the effectiveness of its proprietary Integrated Cognitive Assessment (ICA) platform for early detection of cognitive impairment in populations of Mild Cognitive Impairment (MCI) and Multiple Sclerosis (MS) patients.
Details of the Cognetivity platform that will be included in the presentation are as follows:
- Details on the ICA, a five-minute test delivered via Apple iPads, the results from which are unaffected by culture, language and education, and which can be carried out unsupervised, meaning there is no need for health professionals to administer, a high cost factor with existing tests;
- Data demonstrating that the ICA does not show a learning effect, making it ideal for micro-measurement, a necessity for investigating small changes in subjects' condition;
- Information on the effectiveness of training for improving diagnoses made by Cognetivity's Artificial Intelligence engine and the inclusion of other data points, e.g. demographic data, in order to further enhance its assessment and classification of a subject's mental health; and
- Data describing the ICA's strong correlation with current best standard of care cognitive tests in healthy, MCI, mild Alzheimer's and MS patients.
Select attendees of the meeting include notable academics and industry leaders from major research institutions including Oxford and Cambridge Universities and leading global pharmaceutical companies including AstraZeneca and GlaxoSmithKline.
Cognetivity's CEO, Dr. Sina Habibi said, "It is unusual for an early-stage firm such as ours to be asked to present at this event. We're excited to have the opportunity to share new and positive results from our research and development work to the attending audience of leading academic and industry experts. Our team continues to make significant progress towards the full commercialization of our platform and we look forward to reporting further positive developments in the coming months."
The early detection of dementia, in particular Alzheimer's disease, is a critical unmet need in healthcare, with a recent Alzheimer's Association report stating that the potential savings to healthcare of early dementia diagnosis could be as high as $7.9 trillion in the USA alone. Cognetivity's ICA platform technology is designed to detect some of the earliest signs of cognitive impairment, such as are present in dementia and other neurodegenerative disorders.
Today 50 million people have dementia globally, with 10 million additional cases being recorded annually. This equates to a new case being recorded every three seconds. Currently one out of two sufferers in higher income countries and nine out of 10 cases in lower income countries never receive a formal diagnosis.
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity's ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.
For more information please visit – www.cognetivity.com
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
FORWARD LOOKING STATEMENTS:
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.
The Exchange does not accept responsibility for the adequacy or accuracy of this release
SOURCE Cognetivity Neurosciences Ltd
For further information: Email: email@example.com; For media enquiries contact: Josh Stanbury, Email: firstname.lastname@example.org